Characterisation of the anti-apoptotic function of survivin-ΔEx3 during TNFα-mediated cell death

British Journal of Cancer

Volumn 96, Issue 11, 2007, Pages 1659-1666

  Malcles, M H ^a   Wang, H W ^b,c   Koumi, A ^a   Tsai, Y H ^b   Yu, M ^a   Godfrey, A ^a   Boshoff, C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bcl 2; Caspase 3; Survivin Ex3

Indexed keywords

CASPASE 3; PROTEIN; PROTEIN BCL 2; SURVIVIN; SURVIVIN DELTAEX3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL;

APOPTOSIS; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASM PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249784237     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603768     Document Type: Article

References (36)

1. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152: 43-49
2. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7: 542-547
3. Altieri DC (2004) Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 92: 656-663
4. Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482
5. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921
6. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M (2004) Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 314: 902-907
7. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA (2005) Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24: 1994-2007
8. Chau BN, Cheng EH, Kerr DA, Hardwick JM (2000) Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 6: 31-40
9. Deveraux QL, Reed JC (1999) IAP family proteins - suppressors of apoptosis. Genes Dev 13: 239-252
10. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, Hayes J, Altura RA (2005) Survivin, survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92: 359-365
11. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC (2002) Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115: 575-585
12. Frade JM, Michaelidis TM (1997) Origin of eukaryotic programmed cell death: a consequence of aerobic metabolism? BioEssays 19: 827-832
13. Goyal L (2001) Cell death inhibition: keeping caspases in check. Cell 104: 805-808
14. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776
15. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002) Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86: 737-743
16. Li F (2005) Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92: 212-216
17. Ma L, Huang Y, Song Z, Feng S, Tian X, Du W, Qiu X, Heese K, Wu M (2006) Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ 13: 2079-2088
18. MacFarlane M, Merrison W, Bratton SB, Cohen GM (2002) Proteasomemediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277: 36611-36616
19. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002a) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100: 30-36
20. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD (2002b) Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 9: 1334-1342
21. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59: 6097-6102
22. Meng H, Lu C, Mabuchi H, Tanigawa N (2004) Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 216: 147-155
23. Mund T, Gewies A, Schoenfeld N, Bauer MK, Grimm S (2003) Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum. FASEB J 17: 696-698
24. Ng FW, Nguyen M, Kwan T, Branton PE, Nicholson DW, Cromlish JA, Shore GC (1997) p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol 139: 327-338
25. Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1: 111-121
26. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, Salvesen GS (2001) Structural basis for the inhibition of caspase-3 by XIAP. Cell 104: 791-800
27. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G (2002) CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 275: 44-53
28. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ (2005) Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92: 120-124
29. Sanchez R, Sali A (2000) Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol 143: 97-129
30. Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G (1999) Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 73: 2232-2242
31. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, Blumke K, Wurl P, Schmidt H, Meye A, Hauptmann S (2005) Elevated expression of survivin-splice variants predicts a poor outcome for softtissue sarcomas patients. Oncogene 24: 5258-5261
32. Vaux DL, Silke J (2005) IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6: 287-297
33. Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C (2002) Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J 21: 2602-2615
34. You RI, Chen MC, Wang HW, Chou YC, Lin CH, Hsieh SL (2006) Inhibition of lymphotoxin-beta receptor-mediated cell death by survivin-DeltaEx3. Cancer Res 66: 3051-3061
35. Zhang H, Xu Q, Krajewski S, Krajewska M, Xie Z, Fuess S, Kitada S, Godzik A, Reed JC (2000) BAR: An apoptosis regulator at the intersection of caspases and Bcl-2 family proteins. Proc Natl Acad Sci USA 97: 2597-2602
36. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869-2881